Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism
- Authors
- Lv, Yong-Tao; Zhang, Yun; Liu, Min; Qiuwaxi, Jia-na-ti; Ashwood, Paul; Cho, Sungho Charles; Huan, Ying; Ge, Ru-Cun; Chen, Xing-Wang; Wang, Zhao-Jing; Kim, Byung-Jo; Hu, Xiang
- Issue Date
- 27-8월-2013
- Publisher
- BMC
- Keywords
- Autism; Cord blood mononuclear cell; Umbilical cord-derived mesenchymal stem cell; Cell transplantation
- Citation
- JOURNAL OF TRANSLATIONAL MEDICINE, v.11
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF TRANSLATIONAL MEDICINE
- Volume
- 11
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/102421
- DOI
- 10.1186/1479-5876-11-196
- ISSN
- 1479-5876
- Abstract
- Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism. Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment. Results: There were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05). Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.